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ACOs experienced a 1.95% increase in cost per discharge between 2011 and 2012, 
while cost per discharge among jointly-led ACOs fell by only 1.27%. Analysis of in-
hospital mortality rates did not reveal persistent trend differences. ConClusions: 
Hospitals that adopted the ACO model had more favorable cost trends between 2008 
and 2011 than hospitals that did not adopt the model, which suggests non-random 
selection of providers opting to participate in ACO initiatives. In the post-ACO adop-
tion period, hospitals that were part of jointly-led ACOs had the lowest cost growth, 
suggesting that this ACO structure may be the most effective.
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objeCtives: Determine 30-day, 60-day and 90-day readmission pattern in patients 
hospitalized for heart failure (HF). Methods: A 5% (n= 3,493,434) national sample 
of Medicare beneficiaries was used to assess the frequency of all-cause readmission 
following an HF hospitalization. The data were restricted to individuals enrolled 
in fee-for-service Medicare (not in Medicare Advantage) who were hospitalized at 
least once with a primary diagnosis of HF between July 1, 2005 and December 31, 
2011. For all HF hospitalizations observed during the study period, 30-, 60-, and 
90-day all-cause readmission rates were calculated. For those hospitalizations that 
were followed by subsequent admissions, the median time to readmission was 
also calculated. Results: During the study period, 82,825 individuals experienced 
a total of 134,328 HF hospitalizations. For those 134,328 episodes, 29,998 (22.3%) 
experienced all-cause readmission within 30 days of discharge. The median time to 
readmission was 14 days. The 60-day readmission rate increased to 33.3% (n= 44,720). 
The results indicated that 40.2% of the episodes experienced readmission within 
90-days and the median time to 90-day readmission was 37 days. ConClusions: 
Individuals hospitalized for HF are frequently readmitted. Approximately 1 in 4 
hospitalizations will be followed by a readmission within 30 days, of which half 
would occur within 2 weeks.
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objeCtives: Majority of the studies on epilepsy have been done on adults and few 
studies are available on children with symptomatic epilepsy (SE). This study aims 
to fill this gap by analyzing the effectiveness of anti epileptic drug (AED) therapy in 
children with SE. Methods: Study was conducted in pediatric outpatient neurology 
clinic of public tertiary care hospital. Children aged 2-18 undergoing AED treatment ≥ 
3 months and diagnosed with SE were included. Effectiveness parameters included; 
complete seizure remission (CSR) for 2 years and adverse drug reactions (ADRs). Those 
children who achieved CSR for 2 years with normalization of electroencephalogram 
were eligible to stop AED treatment. Children were followed for 2 years. Results: 123 
children who completed the follow up were included; 73 (59%) were boys and mean 
(SD) age of children was 8.48±0.43 yrs. The major cause was Neurocysticercosis (NCC) 
in 77 (63%), followed by cryptogenic epilepsy 25 (20%), birth asphyxia 7 (6%), infection 
4 (3%), congenital structural defects 3 (3%) tuberculoma 3 (2.4%) and stroke and hypoc-
alcemia in 2 (1.6%) children each. 79 children (64%) were on monotherapy. 80 (65%) 
were prescribed phenytoin, 25 (20.3%) sodium valproate and 18 (15%) carbamazepine. 
70 (57%) children were prescribed albendazole-prednisolone. At follow-up, 82 (67%) 
children had CSR but AED could be stopped in 62 (50%) only. ADRs were reported in 
27 (22%) children. ConClusions: NCC is the major cause of symptomatic epilepsy 
in North India. The pharmacotherapy, primarily being phenytoin is well tolerated and 
efficacious in children with SE. Though two-third of the children had CSR only 50% 
were eligible to stop AED treatment. This study could serve as the basis to determine 
how the treatment of SE differs from idiopathic Epilepsy and whether or not a differ-
ent approach is required to treat children.
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objeCtives: Several studies have described a remarkable interaction between 
Meropenem and Valproic acid (VPA). However, there’s no analysis has been con-
ducted evaluating the influence of different carbapenems on VPA blood level. 
We sought to analyze the influence of Biapenem on VPA blood concentration 
and the risk of seizures. Methods: We retrospectively collected the patients 
who concomitant administrated of VPA and Biapenem, Meropenem as the con-
trol group::Biapenem 37 cases and Meropenem 48 cases. Recorded the informa-
tion as follows: general clinical data, medication, VPA concentration, seizures 
and treatment and so on. Results: Both of Biapenem and Meropenem signifi-
cantly decreased the VPA blood level . The lowest concentrations in Biapenem 
group were higher than Meropenem group(P= 0.046). The mean decrease of VPA 
level in Biapenem group was also less than Meropenem group (70.65±9.64% 
vs 78.83±8.78%,P= 0.01). There were six patients treated with Biapenem and 
Meropenem at different times of infection during taken the VPA. The low-
95% CI= 0.41-0.52; p< 0.0001). ConClusions: Outpatient follow-up within 7 days 
after hospitalization for mental illness was associated with statistically significant 
lower likelihood of 30-day re-admission.
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objeCtives: Problems were lack of a coordinated approach to review and approval 
of order sets across the 4-hospital division; lack of consistent formal review pro-
cess; wide variability in utilization of order sets, and therefore opportunities 
for errors and misalignment with regulatory compliance. Order set review and 
approval cycle time (defined as from the time an order set is drafted or received 
from the system level to when the approval bodies have approved it and it is 
ready for build, QA, and implementation) was also lengthy, impacting key stake-
holder satisfaction and deployment of order sets for Computerized Physician 
Order Entry (CPOE). Objectives were to create one improved process for all four 
hospitals within the division, with 100% of new order sets compliant with the 
improved process going forward, process cycle time decreased to less than 60 days 
initially, and an increase in staff understanding of terms. Methods: Methods 
utilized to improve the process included Lean Six Sigma tools such as project 
charter, Voice of the Customer (VOC), stakeholder analysis, communication plans, 
SIPOC, elevator speeches, project work plan, Value Stream Mapping of the current 
and future processes, data definitions and collection plan, data analysis includ-
ing XmR control charts and capability analyses, fishbone/cause and effect dia-
gram, Improvement Plan, Control Plan, and computer-based learning of order 
set terminology. Results: Following successful phased implementation of the 
improved process, results were a decrease in cycle time from an average of 77.1 
days at baseline to an average of 18.1 days in the post-improvement data collec-
tion period. ConClusions: In addition to decreased cycle time, the benefits of 
an improved process to review and approve order sets include decreased colleague 
time spent on the process, increased colleague understanding of terms and pro-
cess due to developed education, increased goodwill with physicians due to more 
timely approval of requested order sets, potential decrease in regulatory issues 
and increase in quality of care, and improved CPOE adoption.
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objeCtives: Treatment rates for mental health and substance use disorder (MH/
SUD) conditions are low in the U.S. We assessed consumers’ monetary valuation of 
primary care and collaborative care models for treating MH/SUD relative to usual 
care as a potential strategy for improving treatment rates. Methods: We conducted 
a national, survey-embedded randomized vignette experiment of individuals with 
untreated MH/SUD in 2013. 58,928 adults were screened online and categorized as 
meeting criteria for either drug abuse (N= 418) or alcohol abuse (N= 698) based on 
DSM-IV criteria, or a mental health disorder based on a positive K6 score (N= 1,030). 
The 2,146 participants were randomized to view one of three treatment vignettes: 
usual care (N= 726), primary care (N= 697), or collaborative care (N= 723). Participants 
were asked whether they would be willing to enter treatment first if it were free to 
them, and then if they had to pay (for those initially indicating they were willing, 
randomly assigned as $10, $30 or $50) or were paid (for those initially indicating 
they were not willing, randomly assigned in $5 increments between $5 and $25). 
Responses were aggregated to calculate, for each treatment approach, an inverse 
demand function (i.e., proportion of all participants willing to enter treatment at 
each price point). After adjusting for MH/SUD condition, we fit linear regression 
lines through the inverse demand curves. Participants’ average incremental value 
was calculated as the horizontal distance between the linearized inverse demand 
functions. Results: Respondents valued primary care over usual care by $9.00 
(95% confidence interval [CI]: $2.97, $15.04; p= 0.003), and they valued collaborative 
care over usual care by $5.85 (95% CI: -$0.14, $11.85; p= 0.056). ConClusions: Our 
results suggest that low treatment rates for MH/SUD may be addressed by increasing 
the availability of primary care and collaborative care treatment models, which are 
somewhat more appealing to consumers than usual care.
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objeCtives: Providers who have had favorable cost and quality trends may be 
more likely to form Accountable Care Organizations (ACOs) because they expect 
to profit from changes that are already underway within their organization. We 
examine trends in hospital cost per discharge and in-hospital mortality rates among 
hospitals that formed ACOs and those that did not, incorporating several years of 
data preceding ACO formation. Methods: We compared growth rates in cost per 
discharge and in-hospital mortality rates for select conditions. Data were from 2008 
to 2011 (pre-ACO) and 2011 to 2012 (post-ACO) for hospitals that did and did not 
implement ACOs. We also explored whether there were distinct trends based on ACO 
leadership structure. Results: Between 2008 and 2011, the average rate of growth 
in cost per discharge for hospitals that adopted ACOs was less than one-third of the 
rate among hospitals that remained unaffiliated (0.59% vs 2.02%). Among ACOs in 
which the hospital assumed a leadership role, mean cost per discharge declined dur-
ing the pre-ACO period at an average rate of 0.55% for hospital-led ACOs and 1.52% 
for jointly-led ACOs. Cost per discharge during the post-ACO period grew at a rate 
of 1.99% among ACO hospitals and 1.02% among non-ACO hospitals. Hospital-led 
